Multiple new insurance wins expand and improve access to Phexxi® for millions of women

– Medicaid improves Phexxi coverage for more than 3.7 million people in 11 states –

– The largest commercial insurance company in Michigan The Marquis University Plan Pennsylvania Move Phexxi to preferred recipe book mode with $0 Participation and no strings attached, affecting nearly 2.25 million people in total –

San DiegoAnd January 9, 2023 /PRNewswire/ — Evofem Biosciences, Inc. (OTCQB: EVFM) today announced several new insurance wins giving millions of plus-size women access to Phexxi.® (lactic acid, citric acid, potassium bitartrate) for hormone-free contraception.

“Evofem’s continued focus and engagement with payers continues to drive results, expanding and improving access to Phexxi for millions of women across the country,” said Sondra Pelletier, CEO of Evofem.

Three Medicaid awards recently moved Phexxi to preferred formulary status with no strings attached, improving Phexxi’s coverage to more than 3.7 million people in 11 states.

  1. The leading Medicaid provider removed the prior authorization (PA) and moved Phexxi from not preferred to preferred for 14 of its managed Medicaid plans. November 2, 2022. This change has improved Phexxi’s coverage to nearly 3 million people in nine states: GeorgiaAnd New YorkAnd New JerseyAnd VirginiaAnd MarylandAnd IndianaAnd nvAnd Nebraska and Florida.
  2. Mississippi Medicaid removed PA and moved Phexxi from non-preferred to preferred active agent January 1, 2023. Mississippi It has a global preferred drug list, so this change positively impacts both service charges and administered Medicaid beneficiaries — more than 600,000 people.
  3. Phexxi has been added to Indiana’s list of preferred drugs with no effective PA January 1st, 2023. Its previous position was unfavorable with the Palestinian Authority. When Indiana moves to Universal PDL July 1, 2023the state’s 1.4 million people managed Medicaid lives will also have access to Phexxi as preferred without a PA.

Evofem has also expanded its commercial coverage of Phexxi with wins including University Health Plan Marquis in Pennsylvania (effective November 30, 2022) and the biggest commercial motive in Michigan (effective January 1, 2023). These payers serve more than 2.25 million people in total. Both drivers removed the PA and moved Phexxi to preferred formulary mode; Phexxi’s new position is $0 Preferably without restrictions.

Earlier in 2022, Evofem broke avenues for Phexxi with payers including one of the nation’s largest pharmacy benefit managers (PBMs); A highly respected nationally commercial pusher has added Phexxi to the formulary for standard plans nationwide; California’s top payers Hawaii, both without participation for Phexxi patients; And one of the largest payers in Utah, bar none.

Under Section 2713 of the Public Health Services Act (PHS), group health plans and health insurance companies are required to cover preventive care and screenings according to guidance from the Health Resources and Services Administration (HRSA). Section 2713 of the PHS Act came into effect when added by the Affordable Care Act (ACA) in 2010. The HRSA guidelines currently in effect were issued in 2019 and require broad coverage of contraceptive care and services for women. Updated guidelines issued in late 2021 went into effect January 1, 2023For calendar year plans.

in July 2022The Departments of Labor, Health and Human Services, and the Treasury have issued further guidance on birth control coverage to make it clear that group health plans and insurance companies must cover birth control at no cost to individuals. As the new guidance reminds employers, violators may be subject to preventive care coverage requirements for $100 dollars per person per day consumption tax under Section 4980D of the Internal Revenue Code or a civil monetary penalty under PHS Code Section 2723. The guidance states that departments will “take enforcement action as required.”

About Evofem
Evofem Biosciences, Inc. Develops and markets innovative products to address unmet needs in women’s sexual and reproductive health. The first FDA-approved product, Phexxi® (lactic acid, citric acid, and potassium bitartrate), is a hormone-free vaginal contraceptive gel. It comes in a box of 12 pre-filled applicators and is applied 0 to 60 minutes before each sex. Learn more through phexxi.com And evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

About Phexxi
Phexxi is an on-demand method of birth control used to prevent pregnancy. Phexxi is not effective when used after sex. For more information about Phexxi, speak to your healthcare provider and view full product information at www.phexxi.com.

Forward-looking statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor for forward-looking statements” set forth in Section 21E of the Securities Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitations and statements as to the timing and effect move through Indiana to a global PDL. Many factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, including market and other conditions, and you are cautioned not to place undue reliance on these forward-looking statements, which are currently available only as of the date of This press release. Each of these forward-looking statements involves risks and uncertainties. Significant factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences’ assets and business, are disclosed in the company’s SEC filings, including in its annual report on Form 10-K For the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022, and its quarterly report on Form 10-Q for the quarter ending September 30, 2022 filed with the Securities and Exchange Commission on January 6, 2023 and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company undertakes no duty to update any forward-looking statement, except as required by law.

Contacts
Investors:
Amy Raskoff
Senior Vice President, Investor Relations
Evofem Biosciences, Inc.
[email protected]
(917) 673-5775

The media:
[email protected]

Source: Evofem Biosciences, Inc.

Leave a Comment